Repaglinide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Repaglinide: From Type 2 Diabetes to Opsismodysplasia
One-Sentence Summary
Repaglinide is a meglitinide-class oral insulin secretagogue used to manage type 2 diabetes mellitus by stimulating pancreatic β-cell insulin release via K-ATP channel blockade. The TxGNN model’s top prediction links it to Opsismodysplasia, a rare skeletal dysplasia, but this association is currently supported by zero clinical trials and zero publications, and the model’s own mechanistic rationale finds no known biological connection between the two conditions.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 Diabetes Mellitus (established pharmacological classification; not present in this evidence pack’s regulatory dataset) |
| Predicted New Indication | Opsismodysplasia |
| TxGNN Prediction Score | 98.77% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack (DrugBank MOA field marked as a data gap). Based on the mechanistic notes attached to the predictions, Repaglinide acts as a K-ATP channel blocker on pancreatic β-cells, promoting insulin secretion — the pharmacological basis for its established use in type 2 diabetes.
Opsismodysplasia is a rare autosomal-recessive skeletal dysplasia associated with INPPL1 gene mutations, affecting bone growth and development. There is no established biological pathway connecting insulin secretagogue activity to skeletal chondrocyte or growth-plate biology, and the evidence pack itself states this explicitly.
The pack’s own repurposing rationale for this candidate concludes that no known biological association exists between opsismodysplasia and repaglinide’s K-ATP channel mechanism, and that the high TxGNN score likely reflects an indirect knowledge-graph node connection rather than genuine pharmacological relevance. This should be treated as a low-confidence, likely spurious prediction rather than a genuine repurposing signal.
For context, among the ten top-ranked candidates in this pack, only rank #4 (“thiamine-responsive dysfunction syndrome” / Rogers syndrome, TRMA) shows a theoretically plausible link, since its diabetes component has been reported to respond to insulin secretagogues in some case reports — though it too currently has no direct clinical or literature evidence for repaglinide specifically.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EU marketing authorization is currently recorded for Repaglinide in this evidence pack (market status: Not Marketed; 0 authorizations on file).
Safety Considerations
Please refer to the SmPC for safety information.
A Blocking data gap (TFDA/EMA label warnings and contraindications) has been identified and must be resolved before this candidate can enter Stage 1 (S1) safety pre-assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: All ten predicted indications for Repaglinide in this evidence pack are rated Evidence Level L5 (model prediction only, no clinical trials or literature), and the top-ranked candidate (Opsismodysplasia) is explicitly flagged by its own mechanistic rationale as lacking any known biological connection to the drug’s mechanism. Combined with the absence of EU marketing authorization and a Blocking safety data gap, there is currently no basis to advance this candidate.
To proceed, the following is needed:
- DrugBank mechanism of action (MOA) data for Repaglinide
- TFDA/EMA product label warnings, contraindications, and DDI data (Blocking — required before any S1 safety pre-assessment)
- Independent mechanistic or preclinical validation for any of the ten predicted indications, particularly the comparatively more plausible thiamine-responsive dysfunction syndrome (rank #4)
- Continued literature/clinical trial surveillance, as none of the ten candidates currently have supporting registered trials
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.